Physician profile
Nathan Westercamp
NPI 1639441405
$1,434.84
in general payments reported to CMS, 2019-2025
17 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $723 · 2023: $13.15 · 2024: $182 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $679.02 | 2022 | |
| Atricure, INC. | $249.36 | 2022-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Astrazeneca Pharmaceuticals LP | $93.04 | 2024-2025 | Tagrisso |
| Ethicon US, LLC | $53.31 | 2023-2024 | Echelon Flex, Echelon Endopath |
| Merck Sharp & Dohme LLC | $52.55 | 2025 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $42.17 | 2025 | Libtayo |
| Davol INC. | $41.39 | 2025 | Arista |
| Baxter Healthcare | $29.53 | 2024 | Tisseel |
| Takeda Pharmaceuticals U.S.A., INC. | $29.14 | 2025 | Alunbrig |
| Tersera Therapeutics LLC | $26.69 | 2025 | Zoladex |
| Genentech USA, INC. | $22.25 | 2025 | Tecentriq |
| Eisai INC. | $22.10 | 2025 | |
| On Target Laboratories, INC | $21.01 | 2025 | Cytalux |
| Boston Scientific Corporation | $20.31 | 2024 | |
| Coherus Oncology, INC. | $19.54 | 2025 | Loqtorzi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $18.21 | 2024 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Incyte Corporation | $15.22 | 2025 | Monjuvi, Zynyz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Westercamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.